Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India) Ltd has announced that its Board of Directors will convene on July 29, 2026. The primary agenda item is to consider, approve, and take on record the unaudited financial results, both standalone and consolidated, for the quarter ended June 30, 2026. The company has also closed its trading window from June 30, 2026, and it will reopen on August 1, 2026, 48 hours after the declaration of these financial results, in compliance with insider trading regulations.

Nath Bio-Genes (India) Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from July 1, 2026, until 48 hours after the declaration of the Unaudited Financial Results for the quarter ending June 30, 2026. The specific date for the board meeting to approve these results will be communicated separately. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Nath Bio-Genes (India) Ltd. has released the audio transcript of its conference call held on May 5, 2026, at 4:00 PM. The call discussed the audited financial results for the quarter and year ended March 31, 2026. The audio recording is accessible on the company's website.

Nath Bio-Genes (India) Ltd's board meeting on May 4, 2026, approved the standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported revenue from operations of ₹431.6 million for FY26. The board recommended a dividend of ₹2 per equity share (20%) subject to shareholder approval. Mr. Hitesh Rajnikant Purohit was re-appointed as an Independent Director for a second term of five years. M/s K.P. Sahasrabudhe & Co. was appointed as Internal Auditor for FY 2026-27. The remuneration of Managing Director, Mr. Satish Kagliwal, was increased to ₹14.4 million per annum, effective January 1, 2026, subject to shareholder approval.

Nath Bio-Genes (India) Ltd announced audited financial results for the year ended March 31, 2026. The Board recommended a dividend of ₹2 (20%) per equity share. Mr. Hitesh Rajnikant Purohit was re-appointed as an Independent Director for a second term of five years, effective March 30, 2027. M/s K.P. Sahasrabudhe & Co., Chartered Accountants, were appointed as Internal Auditors for FY 2026-27. The remuneration of Mr. Satish Kagliwal, Managing Director, was increased from ₹66,00,000 to ₹1,44,00,000 per annum, effective January 1, 2026, subject to shareholder approval. Revenue from operations stood at ₹431.6 Mn and Profit from Operations before other income, finance costs and Exceptional Items stood at ₹48.6 Mn.

Nath Bio-Genes (India) Ltd has announced an earnings conference call to discuss its financial results for Q4 and the full fiscal year 2026. The call is scheduled for Tuesday, May 5, 2026, at 4:00 PM IST. Key management personnel, including Mr. Satish Kagliwal (Managing Director), Dr. Devinder Khurana (Executive Vice President), and Mr. Amol Gupta (Chief Financial Officer), will participate. The conference call, hosted by Go India Advisors, will provide an opportunity for investors and analysts to engage with the company's leadership regarding its performance and future outlook. Dial-in information and a pre-registration link have been provided for participants.

Nath Bio-Genes (India) Ltd has scheduled a Board of Directors meeting on May 4, 2026, to consider and approve the audited financial results (standalone and consolidated) for the fourth quarter and year ended March 31, 2026. The board will also consider recommending a dividend for the year 2025-26, subject to shareholder approval. The company's trading window, which was closed on March 31, 2026, will reopen on May 6, 2026.

Nath Bio-Genes (India) Ltd has announced the closure of the trading window for dealing in securities of the company. The closure will be in effect from Wednesday, 01st April, 2026 up to 48 hours after the declaration of audited financial results for the quarter and financial year ended on 31st March, 2026. The date of the Board Meeting for the financial results declaration will be informed separately.

Nath Bio-Genes (India) Ltd. has announced its financial results for the quarter and nine months ended on 31st December 2025. The company's revenue from operations stands at 6596.11 lakhs for the quarter and 38590.36 lakhs for the nine months period. The net profit for the period is 4214.01 lakhs. The company's financial results were reviewed by the Audit Committee on 30th January 2026 and approved by the Board of Directors at its meeting held on 31st January 2026.

Nath Bio-Genes (India) Ltd has announced that its Board of Directors will meet on 31st January 2026 to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ending 31st December 2025. The meeting is scheduled as per Regulation 29 and 33 of the Listing Regulations 2015. The company has closed its trading window for insider trading from 31st December 2025 and it will reopen on 3rd February 2026.